Salix Pharmaceuticals Inactive 10-K2011 FY Annual report

Filed: 28 Feb 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: AB, accelerating, accidental, adherence, administered, adulterated, advantage, anesthesia, anniversary, Appalachian, arm, assigned, ban, banned, baseline, Bio, biocompatible, biofeedback, bladder, blind, blocker, brain, branch, breakdown, breast, byTakeda, capacity, carryforward, CE, Cetacea, Chancery, children, Circuit, clause, clearance, Colace, Colonnade, colorectal, compel, complex, composed, congestive, conservative, consumed, coordinate, coordination, Cornerstone, corticosteroid, County, Covidien, CRL, Cubist, Cumberland, dealing, decision, Deferral, deflux, Department, detain, deviate, device, dextranomer, diet, discontinuation, dismissal, doctrine, double, doughnut, draft, DSM, Dulcolax, durability, duty, edema, Edison, efficiency, emerging, enacted, enactment, enjoin, Entereg, environmental, Ernst, estrogen, Euro, evidenced, evolving, excise, Exelsior, export, exported, face, factually, faith, False, faster, fecal, fiber, fiduciary, flat, fluid, forma, forward, fraudulent, functional, GAAP, gap, gas, gel, GERD, Greenville, grew, guarantee, heart, heightened, hierarchy, hole, Hour, hyaluronate, hypertension, IDE, Implantable, implanted, imposition, inadvertent, incontinence, indefinite, induced, inInternal, innovative, Inspector, inter, invasive, Ireland, irreversible, jointly, Justice, Kondremul, Kristalose, lobe, lubricant, LumacanTM, Magnesia, malformation, Mallinckrodt, mandated, Mandatory, manipulating, Medicare, Medtronic, mentioned, merger, merit, MHLW, Milk, Ministry, Miralax, misbranded, mismanagement, Missouri, MNTX, model, motion, movement, mu, navigating, necessarily, nerve, Nevada, Ocean, Oceana, Ono, OPDP, osmotic, OTC, outpatient, parallel, payor, pen, penalty, Pennsylvania, peptic, Perrigo, Philadelphia, Phosphosoda, physiologic, PMA, polymorphic, posted, Postmarket, postpone, PPACA, premarket, pro, progressed, purport, quoted, radioactive, randomized, Ravensburg, reassessed, recertification, recertified, reclassification, rectum, refractory, refund, regular, renal, repair, repeat, Reply, Restated, restrain, RFBM, rheumatoid, Rick, sacral, saline, Scandinavia, scrutinized, SDI, seize, Senokot, shareholder, SI, silicone, simple, simulation, Simultaneously, softener, solesta, Somerset, sphincteroplasty, St, stabilized, Statute, stemming, Stim, stimulant, stimulation, strength, stringent, subsidy, supersede, Supreme, surgical, surveillance, sustain, sustained, Sweden, syringe, Takeda, Tasmania, thereon, tissue, tongue, UC, underlying, uninsured, unobservable, unqualified, unreasonable, unspecified, Uppsala, urinary, vesicoureteral, Vetter, vial, VUR, Wage, warming, week, Welfare, York, Young

Removed: CEO, certified, collateral, computed, continuation, denied, derived, diacol, expiring, franchise, goal, grown, Hengoed, institution, integrated, interim, moved, Mutual, Oakville, Park, Pathoen, Perimeter, predecessor, prevalent, Procedure, protocol, PTY, purgative, reserved, seller, sublease, transfer, ultimate, unenforceability, unviable, WellSpring, Zelnorm

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Salix Pharmaceuticals similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Salix Pharmaceuticals, Ltd. (the “Company”) for the period ended December 31, 2011 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Carolyn J. Logan, President and Chief Executive Officer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report.

/s/ Carolyn J. Logan

Carolyn J. Logan

President and Chief Executive Officer

February 27, 2012